Overview

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

Status:
Recruiting
Trial end date:
2024-11-13
Target enrollment:
Participant gender:
Summary
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.